2,5-Dihydroxycyclohex-2-en | 134926-00-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,5-Dihydroxycyclohex-2-en
• 英文别名: cyclohexene-1,4-diol；1,4-cyclohexenediol；1,4-cyclohexendiol；Cyclohex-1-ene-1,4-diol
• CAS: 134926-00-4
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: QFAGLPRKJJLLME-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-羟基环己酮 在 溶剂黄146 、 potassium nitrate 作用下， 生成 2,5-Dihydroxycyclohex-2-en
  参考文献：
  名称：

  醛和酮的烯醇化：对协同酸碱催化的结构影响

  摘要：

  在一系列取代的乙酸中，在 25 °C 和恒定离子强度 2.0 (NaNO3) 中测量了一系列简单醛和酮的协同酸碱催化烯醇化的三阶项 (kAB)。虽然三阶项的大小与酸 (kA) 或碱 (kB) 催化的速率常数没有直接相关性，但连续速率常数 (kA· kB) 和协调（三阶）速率常数 (kAB)。这意味着只有当一般酸和一般碱项都重要时，协同途径才重要；这将有助于设计其他可能表现出这种协同催化作用的系统。在醛的情况下，该图的斜率为 0.97，与 4-取代环己酮 (0.51) 和其他酮 (0.59) 在乙酸缓冲液中测量的结果相比。丙醛 (2) 的所得布朗斯台德 βAB 值为 0.20，这与...

  DOI：

  10.1021/ja9729544

文献信息

• AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Allen Jennifer R.

  公开号：US20100160280A1

  公开（公告）日：2010-06-24

  Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X 1 , X 2 , and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , X 1 , X 2 , and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  吡啶和嘧啶化合物： 或者是根据说明书中定义的药用可接受盐，其中m、n、R1、R2、R3、R4、R5、R6、R7、X1、X2、X3、X4、X5、X6、X7、X8和Y都有所定义； 或者是根据说明书中定义的药用可接受盐，其中环A、m、n、y、R2、R3、R4、R5、R6、R7、R8、R9、X1、X2和环A都有所定义； 或者是根据说明书中定义的药用可接受盐，其中m、n、y、R2、R3、R4、R5、R6、R7、R9、X1、X2和环A都有所定义；含有它们的组合物以及制备这类化合物的方法。还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法，例如肥胖、非胰岛素依赖型糖尿病、精神分裂症、双相情感障碍、强迫症等。
• PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Allen Jennifer R.

  公开号：US20100125062A1

  公开（公告）日：2010-05-20

  Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  吡啶和嘧啶化合物，以及含有它们的组合物，以及制备这些化合物的方法。本文还提供了治疗通过抑制PDE10可治疗的疾病或疾病的方法，如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症等。
• [EN] HYDROCARBON SYNTHESIS METHODS, APPARATUS, AND SYSTEMS<br/>[FR] PROCÉDÉS, APPAREIL ET SYSTÈMES DE SYNTHÈSE D'HYDROCARBURES
  申请人：MCNEFF CLAYTON V

  公开号：WO2014008355A1

  公开（公告）日：2014-01-09

  Embodiments of the invention include apparatus and systems for hydrocarbon synthesis and methods regarding the same. In an embodiment, the invention includes a process for creating a hydrocarbon product stream comprising reacting a reaction mixture in the presence of a catalyst inside of a reaction vessel to form a product mixture, the reaction mixture comprising a carbon source and water. The temperature inside the reaction vessel can be between 450 degrees Celsius and 600 degrees Celsius and the pressure inside the reaction vessel can be above supercritical pressure for water. In an embodiment, the invention includes an extrusion reactor system for creating a hydrocarbon product stream. The temperature inside the extrusion reactor housing between 450 degrees Celsius and 600 degrees Celsius. Pressure inside the reaction vessel can be above supercritical pressure for water. Other embodiments are also included herein.

  本发明的实施例包括用于合成碳氢化合物的设备和系统以及相关方法。在一种实施例中，本发明包括一种用于创建碳氢化合物产品流的过程，其中在反应容器内，在催化剂的存在下，反应混合物以形成产物混合物，反应混合物包括碳源和水。反应容器内的温度可在450摄氏度至600摄氏度之间，反应容器内的压力可高于水的超临界压力。在一种实施例中，本发明包括一种挤出反应器系统，用于创建碳氢化合物产品流。挤出反应器壳体内的温度在450摄氏度至600摄氏度之间。反应容器内的压力可高于水的超临界压力。本发明还包括其他实施例。
• PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Allen Jennifer R.

  公开号：US20110160182A1

  公开（公告）日：2011-06-30

  Pyrazine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明提供了吡嗪化合物、含有它们的组合物以及制备这些化合物的方法。本发明还提供了治疗通过抑制PDE10可治疗的疾病或疾病的方法，例如肥胖症、非胰岛素依赖性糖尿病、精神分裂症、双相障碍、强迫症等。
• Compounds and pharmaceutical preparations having calcium - regulatory activity
  申请人：University of Lancaster

  公开号：EP0240257A2

  公开（公告）日：1987-10-07

  Pharmaceutical compositions useful in regulating calcium transport across cellular membranes in man and ani­mals are disclosed. The compositions contain plant growth regulators such as abscisic acid and its derivatives. In particular, the compositions contain a compound of the for­mula: or R₁ - Y - R₂ wherein R₁ is an alkyl of up to seven carbons or a saturated or unsaturated six membered carbon ring, which may be sub­stituted; R₂ is a cyano group, a thio or hydroxy lower alkyl group or a group containing a carbonyl, most commonly a carboxyl group; R₃ is hydrogen or lower alkyl; R₄ is hydro­gen, lower alkyl or halide; R₅ is hydrogen or hydroxy; R₆ is hydrogen, carboxy or carboxy lower alkyl, or R₅ and R₆ form a bond between the carbons to which they are attached or with the carbons to which they are attached form a carbon ring; or R₂ and R₆ together with the carbon to which they are bonded form a heterocyclic ring; n is 0 or 1, with the proviso that when n is 0, R₂ is an acyl group; X is -CH₂-, -­CH=CH-, -CH₂-CH₂-, -CH₂-NH-, -CH₂-O-, -CH₂-S- or -NH-CO-; and Y is a carbocyclic group bonded to R₁ and R₂ through a single carbon. The compositions are formulated for oral, parenteral or other form of administration in dosages neces­sary to effect the desired change in calcium flux. Daily doses of 0.01 to 200 mg/kg in one or more doses are contem­plated. Dosage units may be formulated with any pharma­ceutically acceptable carrier which is compatible with the active ingredient.

  本发明公开了可用于调节人和动物细胞膜钙转运的药物组合物。这些组合物含有植物生长调节剂，如脱落酸及其衍生物。特别是，组合物中含有一种式的化合物： 或 R₁ - Y - R₂ 其中，R₁ 是最多七个碳原子的烷基或饱和或不饱和的六分子碳环，可以被取代；R₂ 是氰基、硫代或羟基低级烷基或含有羰基的基团，最常见的是羧基；R₃ 是氢或低级烷基；R₄ 是氢、低级烷基或卤化物；R₅ 是氢或羟基；R₆ 是氢、羧基或羧基低级烷基，或 R₅ 和 R₆ 在所连接的碳之间形成键，或与所连接的碳一起形成碳环；或 R₂ 和 R₆ 与所连接的碳一起形成杂环；n 为 0 或 1，但当 n 为 0 时，R₂ 为酰基；X 为-CH₂-、-CH=CH-、-CH₂-CH₂-、-CH₂-NH-、-CH₂-O-、-CH₂-S-或-NH-CO-；Y 是通过一个碳与 R₁ 和 R₂ 键合的碳环基团。组合物配制成口服、肠外或其他形式的给药剂量，以实现所需的钙通量变化。日剂量为 0.01 至 200 毫克/千克，可考虑一次或多次给药。剂量单位可与任何与活性成分相容的药学上可接受的载体配制。